Safety Shot Sells Out on First Day Online at www.DrinkSafetyShot.com

2 years ago

Safety Shot, Inc. Safety Shot Sells Out on First Day Online at www.DrinkSafetyShot.com Company had successful West Coast Launch December…

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

2 years ago

   Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory…

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited

2 years ago

KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology…

Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care

2 years ago

Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant…

Angle PLC Announces Broker Announcement

2 years ago

GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating…

Angle PLC Announces Parsortix Unlocks Opportunities for Drug Discovery

2 years ago

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERYHarvested CTCs reveal gene expression profile associated with development…

Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH

2 years ago

POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapiesLONDON, UK / ACCESSWIRE / December 11, 2023 /…

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

2 years ago

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized…

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

2 years ago

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single…

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

2 years ago

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt…